drugset
drugset / Trial / NCT04433234

Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

NCT04433234 ↗

Phase 2 Active not recruiting 8 enrolled Daiichi Sankyo
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, long-term, extension, phase 2 study to evaluate the safety and efficacy of long-term treatment with DS-5141b in patients with DMD who have completed DS5141-A-J101.

Timeline

Start
2020-06-30
Primary completion
2027-01-31
Completion
2027-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject DS-5141b Unknown 2 mg/kg Subcutaneous
Subject DS-5141b Unknown 6 mg/kg Subcutaneous

Indications

Duchenne muscular dystrophy